What is Zivo Bioscience Inc?
, together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
ZIVO · Verdict
Moderate reward · elevated risk
ZIVO's standout is volatility; profitability and cash flow weigh on the picture.
Based on 88% data coverage
ZIVO · Verdict
Top decile vs peers
-8513% net margin · -3956% ROE
-2744% free-cash-flow margin
Model-based scoring. For information only — not financial advice.
, together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 36.55M.
The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.